阿貝西利 (Chinese Wikipedia)
Analysis of information sources in references of the Wikipedia article "阿貝西利" in Chinese language version.
refsWebsite
Global rank
Chinese rank
1st place
1st place
low place
low place
low place
low place
6,094th place
4,939th place
low place
low place
5,225th place
4,888th place
ascopost.com
- LY2835219 Shows Strong Single-Agent Activity in Preliminary Study in Metastatic Breast Cancer. [2021-09-05]. （原始内容存档于2015-09-18）.
clinicaltrials.gov
- A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (MONARCH 3). [2021-09-05]. （原始内容存档于2021-06-04）.
confex.com
ash.confex.com
doi.org
- Lu J. Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer. Journal of Hematology & Oncology. August 2015, 8 (1): 98. PMC 4534142
. PMID 26264704. doi:10.1186/s13045-015-0194-5. - The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell. October 1991, 67 (2): 293–302. PMID 1655277. doi:10.1016/0092-8674(91)90181-w.
- Abemaciclib induces atypical cell death in cancer cells characterized by formation of cytoplasmic vacuoles derived from lysosomes.. Cancer Sci. Jun 2020, 111 (6): 2132–2145. PMC 7293084 . PMID 32304130. doi:10.1111/cas.14419.
- A synthesis of abemaciclib utilizing a Leuckart–Wallach reaction. Tetrahedron Letters. February 2015, 56 (7): 949–951. doi:10.1016/j.tetlet.2014.12.082.
fda.gov
- FDA approves new treatment for certain advanced or metastatic breast cancers (新闻稿). Food and Drug Administration. 28 September 2017 [2023-02-03]. （原始内容存档于2019-04-23）.
lilly.com
investor.lilly.com
lww.com
journals.lww.com
- Digiulio, Sarah. FDA's Breakthrough Therapy Designation to Abemaciclib for Breast Cancer. Oncology Times (LWW Journals). 8 October 2015 [30 March 2016]. （原始内容存档于2021-06-04）.
nih.gov
ncbi.nlm.nih.gov
- Lu J. Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer. Journal of Hematology & Oncology. August 2015, 8 (1): 98. PMC 4534142 . PMID 26264704. doi:10.1186/s13045-015-0194-5.
- The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell. October 1991, 67 (2): 293–302. PMID 1655277. doi:10.1016/0092-8674(91)90181-w.
- Abemaciclib induces atypical cell death in cancer cells characterized by formation of cytoplasmic vacuoles derived from lysosomes.. Cancer Sci. Jun 2020, 111 (6): 2132–2145. PMC 7293084 . PMID 32304130. doi:10.1111/cas.14419.
oncotherapynetwork.com
- Abemaciclib Receives FDA Approval for Certain Metastatic Breast Cancers. Sept 2017. [2021-09-05]. （原始内容存档于2018-12-19）.
s3-us-west-2.amazonaws.com
- Highlights of Prescribing Information for Verzenio (PDF). September 2017 [2021-09-05]. （原始内容存档 (PDF)于2021-09-05）.
web.archive.org
- Digiulio, Sarah. FDA's Breakthrough Therapy Designation to Abemaciclib for Breast Cancer. Oncology Times (LWW Journals). 8 October 2015 [30 March 2016]. （原始内容存档于2021-06-04）.
- FDA approves new treatment for certain advanced or metastatic breast cancers (新闻稿). Food and Drug Administration. 28 September 2017 [2023-02-03]. （原始内容存档于2019-04-23）.
- Highlights of Prescribing Information for Verzenio (PDF). September 2017 [2021-09-05]. （原始内容存档 (PDF)于2021-09-05）.
- LY2835219 Shows Strong Single-Agent Activity in Preliminary Study in Metastatic Breast Cancer. [2021-09-05]. （原始内容存档于2015-09-18）.
- Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma. [2021-09-05]. （原始内容存档于2021-06-03）.
- Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival, Eli Lilly, 20 March 2017. [2021-09-05]. （原始内容存档于2017-12-01）.
- Abemaciclib Receives FDA Approval for Certain Metastatic Breast Cancers. Sept 2017. [2021-09-05]. （原始内容存档于2018-12-19）.
- A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (MONARCH 3). [2021-09-05]. （原始内容存档于2021-06-04）.